Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA3 | P07451 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 1/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617943 | 1.00 | LMNA (0.64) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14419736 | 0.94 | LMNA (0.57) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14419799 | 0.94 | LMNA (0.57) | LMNACA12CA1CA2CA3 | |
| Trifluoroacetic Acid SCHEMBL4471386 | 0.89 | LMNA (0.56) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13788522 | 0.82 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL951298 | 0.82 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10959845 | 0.82 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3713795 | 0.81 | LMNA (0.60) | LMNACA12CA1CA2CA3 | |
| Urea SCHEMBL14776158 | 0.81 | LMNA (0.59) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2617906 | 0.79 | LMNA (0.45) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724782-A | Preparation and removal method of levetiracetam impurities | 浙江华海药业股份有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | claimed |
| US-4115579-A | 2-OXO-1-PYRROLIDINEACETAMIDE, 2-(2-OXOPYRROLIDINO)PROPIONAMIDE OR 2-(2-OXOPYRROLIDINO)BUTYRAMIDE | U C B, SOCIETE ANONYME (BE) | 1978-09-19 | — | — | US | claimed |
| US-20250382265-A1 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | UNIV JAGIELLONSKI (PL) | 2025-12-18 | — | — | US | disclosed |
| US-20250382265-A1 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | UNIV JAGIELLONSKI (PL) | 2025-12-18 | — | — | US | disclosed |
| EP-4623910-A3 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | UNIWERSYTET JAGIELLONSKI (PL) | 2025-12-10 | — | — | EP | disclosed |
| EP-4623910-A2 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | UNIWERSYTET JAGIELLONSKI (PL) | 2025-10-01 | — | — | EP | disclosed |
| EP-4623910-A2 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | UNIWERSYTET JAGIELLONSKI (PL) | 2025-10-01 | — | — | EP | disclosed |
| US-12421189-B2 | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | UNIWERSYTET JAGIELLONSKI (PL) | 2025-09-23 | — | — | US | disclosed |
| US-12421189-B2 | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | UNIWERSYTET JAGIELLONSKI (PL) | 2025-09-23 | — | — | US | disclosed |
| EP-3956310-B1 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | UNIV JAGIELLONSKI (PL) | 2025-08-06 | — | — | EP | disclosed |
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| CN-1268111-A | Iodopropagylamine compounds, and industrial antimicrobial and antifungal agents, algicides, and antifouling agents containing the same | NISSAN CHEMICAL IND LTD (JP) | 2000-09-27 | — | — | CN | disclosed |
| US-4908202-A | Administering known dosage of piracetam to subject, withdrawing blood samples at spaced time intervals, measuring differences in piracetam present in samples | CASSELLA AKTIENGESELLSCHAFT (DE) | 1990-03-13 | — | — | US | disclosed |
| US-4115579-A | 2-OXO-1-PYRROLIDINEACETAMIDE, 2-(2-OXOPYRROLIDINO)PROPIONAMIDE OR 2-(2-OXOPYRROLIDINO)BUTYRAMIDE | U C B, SOCIETE ANONYME (BE) | 1978-09-19 | — | — | US | disclosed |
| US-4115579-A | 2-OXO-1-PYRROLIDINEACETAMIDE, 2-(2-OXOPYRROLIDINO)PROPIONAMIDE OR 2-(2-OXOPYRROLIDINO)BUTYRAMIDE | U C B, SOCIETE ANONYME (BE) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | LMNA 705/4885CA12 2744/4885CA1 290/4885 |
| US-20250382265-A1 | MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERS | SLC1A2, GRIN2A, GRIN2D | LMNA 1231/4885CA12 4480/4885CA1 1105/4885 |
| US-12421189-B2 | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | SLC1A2, GRIN2A, GRIN2D | LMNA 1231/4885CA12 4480/4885CA1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.